Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Sep 2:104:adv40634.
doi: 10.2340/actadv.v104.40634.

Bullous Pemphigoid that Developed During Nemolizumab Treatment for Atopic Dermatitis: Two Case Reports

Michie Katsuta  1 , Ryoichi Kamide  2 , Yozo Ishiuji  3 , Yoshimasa Nobeyama  3 , Akihiko Asahina  3
Affiliations
Case Reports

Bullous Pemphigoid that Developed During Nemolizumab Treatment for Atopic Dermatitis: Two Case Reports

Michie Katsuta et al. Acta Derm Venereol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

NK and YN received research funding and honorarium as a speaker from Maruho. YI received an honorarium as a speaker from Maruho, Sanofi, AbbVie, Pfizer, Eli Lilly, and Otsuka. The other authors declare they have no conflicts of interest.

Figures

Fig. 1
Fig. 1
(a) Clinical findings before nemolizumab treatment (Eczema Area and Severity Index 36.8, Investigator’s Global Assessment 3, and itch Visual Analog Scale 90, eosinophil count 998/μL, TARC 1,658 pg/mL, IgE 356 IU/mL). (b–d) Clinical findings at the time of blister appearance (itch Visual Analog Scale 10, eosinophil count 1,558/μL, TARC 6338 pg/mL, IgE 794 IU/mL). (e) Histopathological findings (loupe image, haematoxylin, and eosin staining). A subepidermal blister and eosinophilic infiltration in the upper dermis is evident. (f) Direct immunofluorescence (×100). Linear IgG deposition is shown at the dermal–epidermal junction.
Fig. 2
Fig. 2
(a) Clinical findings before nemolizumab treatment (Eczema Area and Severity Index 11, Investigator’s Global Assessment 3, and itch Visual Analog Scale 85, eosinophil 835/μL, TARC 1,134 pg/mL, IgE 3977 IU/mL). (b–e) Clinical findings at the time of blister appearance (eosinophil 1938/μL, TARC 4,463 pg/mL, IgE 5726 IU/mL. (f) Histopathological findings (loupe image, haematoxylin, and eosin staining). A subepidermal blister and eosinophilic infiltration in the upper dermis were evident. (g) Direct immunofluorescence (×100). Linear IgG deposition is evident at the dermal–epidermal junction.
See this image and copyright information in PMC

References

    1. Kabashima K, Matsumura T, Komazaki H, Kawashima M, Nemolizumab JPSG. Trial of nemolizumab and topical agents for atopic dermatitis with pruritus. N Engl J Med 2020; 383: 141–150. 10.1056/NEJMoa1917006 - DOI - PubMed
    1. Watanabe Y, Ishiuji Y, Ogawa-Tominaga M, Katsuta M, Asahina A. Real-world clinical efficacy of nemolizumab in Japanese patients with atopic dermatitis. Itch 2023; 33: 691–692. 10.1097/itx.0000000000000071 - DOI
    1. Kabashima K, Matsumura T, Komazaki H, Kawashima M, Nemolizumab JPaSG. Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate-to-severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III, long-term studies. Br J Dermatol 2022; 186: 642–651. 10.1111/bjd.20873 - DOI - PMC - PubMed
    1. Masuyuki R, Sato E, Imafuku S. A case of bullous pemphigoid following administration of anti-IL-31 receptor A antibody. J Dermatol 2024. Mar 20 [Online ahead of print]. 10.1111/1346-8138.17171 - DOI - PubMed
    1. Marazza G, Pham HC, Schärer L, Pedrazzetti PP, Hunziker T, Trüeb RM, et al. . Incidence of bullous pemphigoid and pemphigus in Switzerland: a 2-year prospective study. Br J Dermatol 2009; 161: 861–868. 10.1111/j.1365-2133.2009.09300.x - DOI - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources